PrintBio
PrintBio, Inc. is a U.S. clinical- and commercial-stage biotechnology company that develops and sells FDA 510(k)-cleared 3D-bioprinted bioresorbable surgical mesh (DynaFlex PSM, DynaForm PSM) to surgeons, hospitals, and health systems, while also advancing bioprinted kidney tissue programs via the ARPA-H PRINT consortium.
- Company typePrivate
- Founded2024
- HeadquartersSurfside, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What PrintBio does
PrintBio, Inc. is a clinical- and commercial-stage biotechnology company focused on 3D-bioprinted living implants and bioresorbable surgical mesh for regenerative medicine. The company markets a two-brand portfolio of FDA 510(k)-cleared Programmable Surgical Mesh—DynaFlex™ PSM and DynaForm™ PSM—built on proprietary MetaFlex™ and MetaDirectional Flex™ technologies that allow surgeons to regulate flexibility along any vector or within specific zones of the mesh, an attribute not available in conventional static filament meshes. Both products are bioresorbable and are produced in what PrintBio describes as the world's first clinical-grade manufacturing facility for living bioprinted implants, located in Long Island City, NY, featuring cGMP ISO7 and ISO8 Clean Rooms with vertically integrated production of collagen, cells, bioprinters, and finished surgical constructs.
PrintBio generates revenue primarily through direct enterprise sales of its surgical mesh products to surgeons, hospitals, and health systems performing soft tissue repair, hernia repair, and surgical reconstruction. A secondary revenue stream comes from professional services tied to its participation in the ARPA-H PRINT Program, where PrintBio contributes 3D bioprinting and translational manufacturing expertise to a $24.8 million, five-year initiative led by Wake Forest Institute for Regenerative Medicine to develop on-demand bioprinted, vascularized kidney tissue from patients' own cells for end-stage renal disease treatment. The company distributes exclusively through a direct field-sales motion in the United States, supported by a dedicated VP of Commercial Strategy and a Director of Sales Infrastructure and Enablement, and uses a "Request a Rep Visit" channel on its corporate website to drive surgeon engagement.
The company is privately held, headquartered in Surfside, FL, with its R&D and manufacturing facility in Long Island City, NY, and traces its technical lineage and leadership team to 3DBio Therapeutics, which achieved the first-ever FDA-authorized living tissue implant. The company is led by Founder, Chairman and CEO Kevin Slawin, M.D.—a former robotic oncologic surgeon who previously led Bellicum Pharmaceuticals to a $161 million IPO—and is advised by a leadership team including alumni of Pfizer, AbbVie, Bristol-Myers Squibb, LifeCell, and Organogenesis.
PrintBio firmographics
Firmographics- Name
- PrintBio
- Legal name
- PrintBio, Inc.
- Website
- https://printbio.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- PrintBio, Inc. is a U.S. clinical- and commercial-stage biotechnology company that develops and sells FDA 510(k)-cleared 3D-bioprinted bioresorbable surgical mesh (DynaFlex PSM, DynaForm PSM) to surgeons, hospitals, and health systems, while also advancing bioprinted kidney tissue programs via the ARPA-H PRINT consortium.
- Ownership category
- akta.pro rank
PrintBio industry classification
Industry- Product category
- Regenerative Medicine Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- 3D Bioprinting & Biofabrication (HLAAAGAC)
- akta.pro secondary industry
- Medical & Dental 3D Printing Services (patient-specific devices, dental labs) (IMAAADAG)
Keywords
Where PrintBio is headquartered
LocationHeadquarters
- HQ city
- Surfside
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
PrintBio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Surgical Mesh Products: PrintBio generates revenue from commercializing its FDA 510(k)-cleared DynaFlex and DynaForm Programmable Surgical Mesh products to surgeons, hospitals, and health systems.
- ARPA-H PRINT Program Contribution: PrintBio contributes its 3D bioprinting and translational manufacturing expertise to the ARPA-H PRINT Program ($24.8M over 5 years) led by Wake Forest Institute for Regenerative Medicine, for developing bioprinted kidney tissue.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
PrintBio product offering
Product offeringCore offering
PrintBio develops, manufactures and commercializes 3D-printed bioresorbable Programmable Surgical Mesh products — DynaFlex™ PSM and DynaForm™ PSM — for soft tissue repair and reinforcement. The meshes are FDA 510(k)-cleared, leverage proprietary MetaFlex™ and MetaDirectional Flex™ technologies that allow flexibility and stability to be tuned along any vector or in targeted zones, and are produced in a vertically integrated cGMP clinical-grade facility. The company is also advancing bioprinted living tissue implants for regenerative medicine applications including kidney tissue under the ARPA-H PRINT Program.
Product overview
PrintBio offers a two-brand portfolio of Programmable Surgical Mesh (PSM) — DynaFlex™ PSM and DynaForm™ PSM. Both products are 3D-printed bioresorbable FDA 510(k)-cleared surgical meshes that add PrintBio's proprietary MetaDirectional Flex™ capabilities to the company's first-ever 3D-printed bioresorbable surgical mesh technology. DynaFlex™ PSM specializes in empowering surgeons to precisely tailor flexibility and stability through its MetaFlex™ technology, while DynaForm™ PSM delivers three-dimensional mesh constructs designed to provide immediate soft tissue support and a basis for long-term strength.
Differentiator
Problem solved
Functional benefit
Brands
- DynaFlex™ PSM: 3D-printed bioresorbable FDA 510(k)-cleared surgical mesh with MetaFlex technology that enables surgeons to precisely tailor flexibility and stability in any direction or within targeted zones of the mesh.
- DynaForm™ PSM
Products and services
- DynaFlex™ Programmable Surgical Mesh (PSM) DynaFlex™ PSM is a 3D-printed bioresorbable FDA 510(k)-cleared surgical mesh for surgeons performing soft tissue repair and reinforcement. It incorporates MetaFlex™ technology enabling precision tailoring of flexibility and stability in any direction or within targeted zones of the mesh, and its 3D-printed architecture is devoid of cross-filament knots, weaves or loops that harbor bacteria. It provides stability where needed and flexibility where desired, with minimal deformation under post-operative mesh tension and superior fluid transmission compared with filament meshes.
- DynaForm™ Programmable Surgical Mesh (PSM) DynaForm™ PSM is a 3D-printed bioresorbable FDA 510(k)-cleared surgical mesh that delivers customized 3D mesh constructs regulating and varying flexibility along any vector and in any zone. It provides immediate soft tissue support and a basis for long-term strength, with quick and simple contoured fit that conforms to the patient's natural shape and avoids mesh cutting, wrinkling, and folding. Designed for surgeons and hospitals performing soft tissue repair, hernia repair and surgical reconstruction.
Quantifiable outcome
- Minimal mesh space deformation during post-operative abdominal strain compared to filament meshes
- +1 more outcomes
Companies that use PrintBio
Customer profileSegments3 records
Ideal customer profiles3 records
PrintBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
PrintBio partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Wake Forest Institute for Regenerative Medicine (WFIRM)corePrintBio contributes 3D bioprinting and translational manufacturing expertise to the ARPA-H PRINT Program led by WFIRM. The program aims to develop on-demand bioprinted kidney tissue for transplantation to address the nation's organ shortage. PrintBio will produce vascularized kidney tissue from patients' own renal cells for treating end stage renal disease. WFIRM has committed to creating a manufacturing and commercialization plan to ensure scalability.
- 3DBio TherapeuticscorePrintBio leverages its track record from 3DBio Therapeutics' pioneering FDA-authorized work. The company brings clinical bioprinting expertise including DynaFlex and DynaForm platforms derived from this experience.
- University of MarylandminorResearch partner in the ARPA-H PRINT Program alongside WFIRM and PrintBio for developing bioprinted, vascularized kidney tissue from patients' own cells.
- Rice UniversityminorResearch partner in the ARPA-H PRINT Program alongside WFIRM and PrintBio for developing bioprinted, vascularized kidney tissue from patients' own cells.
- University of Texas – El PasominorResearch partner in the ARPA-H PRINT Program alongside WFIRM and PrintBio for developing bioprinted, vascularized kidney tissue from patients' own cells.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
PrintBio competitors and assessment
Company assessmentEmerging players
- Organovo: Public bioprinting pioneer (NASDAQ: ONVO) developing functional human tissue for therapeutic and research applications. Closely comparable on technology and TAM (3D-bioprinted human tissue), though at a different scale and pivoted to disease-modeling/research markets.
- BICO (Cellink): Public company (STO: BICO) providing bioprinters, bioinks, and regenerative medicine lab consumables. Comparable as a 3D bioprinting ecosystem player; supplies infrastructure to many academic bioprinting groups, overlapping with PrintBio's technology stack.
- Aspect Biosystems: Canada-based bioprinting company developing bioprinted tissue therapeutics with pharma partnerships (e.g., Novo Nordisk). Comparable emerging bioprinting platform with similar long-term vision of bioprinted therapeutics, though focused on partnership-driven rather than direct medical-device commercialization.
- CollPlant Biotechnologies: Israel-based regenerative medicine company (NASDAQ: CLGN) developing recombinant human collagen and bio-printed tissues including breast implants and orthopedic products. Strong technological peer in bioprinted living implants and rhCollagen-based matrices.
Broad incumbents
- Ethicon (Johnson & Johnson): J&J's surgical solutions division and the dominant global hernia/soft-tissue mesh franchise (Proceed, Physiomesh, Ethicon Mesh). Largest incumbent PrintBio must displace in surgeon preference and GPO contracting.
- BD (Bard): Becton Dickinson owns the legacy Davol hernia mesh franchise (Ventralight, Phasix). One of the top three surgical mesh incumbents PrintBio competes against in hospital ORs.
- Organogenesis: Public regenerative medicine company (NASDAQ: ORGO) selling bioengineered skin substitutes and surgical wound care products. Comparable as a tissue-engineering and regenerative-medicine player with FDA-cleared biologicals marketed into surgical channels—directly overlapping PrintBio's hospital/surgeon GTM.
- Integra LifeSciences: Public medical device company (NASDAQ: IART) with a major regenerative tissue technologies and surgical mesh portfolio including DuraGen and Integra Mesh. Direct competitor in dural/bioresorbable surgical matrices and a likely strategic acquirer of PrintBio's PSM platform.
- Medtronic (Hernia Mesh): Major surgical mesh and hernia repair portfolio acquired through Covidien, including Parietex and ProGrip lines. Competes head-to-head with PrintBio in soft-tissue reinforcement and laparoscopic hernia repair.
Direct peers
- 3DBio Therapeutics: PrintBio's predecessor entity that achieved the first FDA-authorized living tissue implant (AuriNovo for microtia). PrintBio's leadership (Bachrach) and platforms (DynaFlex/DynaForm) derive directly from 3DBio's pioneering work—making it the most directly comparable peer despite the corporate lineage.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
PrintBio social profiles
Digital presencePrintBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
PrintBio leadership team
Management profileNumber of profiles
Profiles9 records
PrintBio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PrintBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PrintBio
What does PrintBio do?
PrintBio develops, manufactures and commercializes 3D-printed bioresorbable Programmable Surgical Mesh products — DynaFlex™ PSM and DynaForm™ PSM — for soft tissue repair and reinforcement. The meshes are FDA 510(k)-cleared, leverage proprietary MetaFlex™ and MetaDirectional Flex™ technologies that allow flexibility and stability to be tuned along any vector or in targeted zones, and are produced in a vertically integrated cGMP clinical-grade facility. The company is also advancing bioprinted living tissue implants for regenerative medicine applications including kidney tissue under the ARPA-H PRINT Program.
Is PrintBio a public or private company?
PrintBio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was PrintBio founded?
PrintBio was founded in 2024. It employs 1 to 10 people.
Where is PrintBio based?
PrintBio is headquartered in Surfside, United States, in the North America region.
How does PrintBio make money?
Two revenue lines are on record. Surgical Mesh Products are the primary driver. The others are ARPA-H PRINT Program Contribution.
Who are PrintBio's main competitors?
Emerging players on record are Organovo, BICO (Cellink), Aspect Biosystems and CollPlant Biotechnologies. Broad incumbents are Ethicon (Johnson & Johnson), BD (Bard), Organogenesis, Integra LifeSciences and Medtronic (Hernia Mesh). 3DBio Therapeutics is listed as a direct peer.
Does PrintBio have an API?
No public API is recorded for PrintBio.
What industry is PrintBio in?
PrintBio's product category is Regenerative Medicine Devices. Its primary akta.pro industry code is HLAAAGAC, 3D Bioprinting & Biofabrication, with a secondary code of IMAAADAG, Medical & Dental 3D Printing Services (patient-specific devices, dental labs). Its NAICS code is 339113 and its SIC code is 3841.